Shares of troubled Cambridge Heart (NSDQ:CAMH) continued to spiral as the company announced that it’s winding down its business operations.
Cambridge Heart prepares to shutter operations
Cambridge Heart Inc.
Cambridge Heart chairman, ex-CEO both resign | Personnel Moves
Cambridge Heart (NSDQ:CAMH) said chairman and interim president Roderick de Greef and former president & CEO Ali Haghighi-Mood have both resigned from the medical device company.
Cambridge Heart jumps 35% on Q3 results
Cambridge Heart (NSDQ:CAMH) remained in the red in its 3rd quarter after the company restructured its operations in July, but narrowed its losses by 16.6%.
Teleflex closes $276M LMA buyout | Wall Street Beat
LeMaitre Vascular pays $5M for Neovasc’s XenoSure | Wall Street Beat
LeMaitre Vascular (NSDQ:LMAT) said it will pay $4.6 million for Neovasc‘s (NYSE:NVC) XenoSure vascular patch, used to repair blood vessels.
CareFusion delays annual report, gets delisting NYSE warning | Wall Street Beat
CareFusion (NYSE:CFN) shares are down slightly today after the medical device company said it would be late in filing its annual report with the SEC, which triggered a delisting warning from the New York Stock Exchange.
CareFusion said it’s negotiating with the securities regulator over how to account for leases of its Pyxis medicine dispensing devices.
Abiomed swings to 2011 black on record Q4 revenues | Earnings Roundup
Abiomed (NSDQ:ABMD) set off a Wall Street roller coaster with its latest earnings release, in which the Danvers, Mass.-based heart pump maker posted its 1st profitable year in a decade and a half.
The 3 months ended March 31 made up Abiomed’s "best quarter and year in company history, in terms of number of patients supported, revenue growth, and profitability," chairman, president & CEO Michael Minogue said in prepared remarks.
Bovie swings to 2011 black | Earnings Roundup
HeartWare lands FDA OK for extended trial ahead of PMA review | Regulatory Roundup
“Exit hangover” casts a pall on private equity | Wall Street Beat
Private equity players are in for some stiff competition this year, as large-cap PE shops invade the middle-market space, according to a report from PE stalwart Bain & Co.
The company’s Global PE Report details a huge “exit overhang” – more aptly deemed an “exit hangover” by PE Hub’s Jonathan Marino – as PE-backed companies seek exits.
And the mega-deals of the past 10 years or so are a thing of the past, according the report, as detailed by Marino.
Carticept closes $10M round from SonoSite, others | Funding Roundup
Carticept Medical closed a $10 million financing led by existing investors Domain Associates, New Enterprise Associates and SonoSite Inc.
The Alpharetta, Ga.-based company said it will use the proceeds to fund the commercial launch of its Navigator computer-controlled drug delivery system. The device uses ultrasound guidance to deliver medications for joint pain.
